La Jolla's GCS-100 Improves Kidney Function In Study

La Jolla Pharmaceutical Co announced positive top-line results from its Phase II trial evaluating GCS-100 for treatment in chronic kidney disease (CKD). The company’s shares rose about 40 percent in extended trading following the news.
Source: Pharmaceutical Online News - Category: Pharmaceuticals Source Type: news